Quantitative GLP-1 receptor imaging correlated to ex vivo distribution of In-111-exendin

Quantitative GLP-1 receptor imaging correlated to ex vivo distribution of In-111-exendin - GLP-1-ex-vivo

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

NL-OMON

Registry ID

NL-OMON44912

Enrollment

Registered

2014-05-07

Start date

2015-11-16

Completion date

Unknown

Last updated

2024-04-23

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

diabetes

Interventions

None listed

Eligibility

Age

18 Years to 99 Years

Inclusion criteria

Inclusion criteria: Scheduled for partial or complete pancreatectomy or complete drainage procedure in case of chronic pancreatitis, Intraductal papillary mucinous neoplasm (IPMN) or pancreatic cancer at Radboudumc

Exclusion criteria

Exclusion criteria: * Resection of only small part of the pancreas without possibility to safely sample other pancreatic parts * Breast feeding * Pregnancy or the wish to become pregnant within 6 months * Creatinine clearance below 40ml/min * Liver disease defined as aspartate aminotransferase or alanine aminotransferase level of more than three times the upper limit of normal range * Age

Design outcomes

Primary

Measure	Time frame
Quantitative determination of the uptake of In-111-exendin into the pancreas in all subjects as determined by 3D SPECT imaging in order to correlate the uptake to the ex vivo distribution and accumulation of the tracer in the pancreas with the BCM.	—

Secondary

Measure	Time frame
* Validation of the 111In-exendin distribution and accumulation in the pancreas * Determination of the uptake ratio of 111In-exendin between the endocrine and exocrine pancreas by quantitative analysis autoradiography * Determination of the radioactivity concentration in the pancreas by quantitative analysis of SPECT images to validate of in vivo measurement of the pancreatic 111In-exendin uptake * Validation of the correlation between BCM and 111In-exendin uptake (determined ex vivo and in vivo) * Determination of the beta cell function of the patients by oral glucose tolerance testing and arginine stimulation testing to evaluate the relationship between BCM and beta cell function * Determination of 111In-exendin uptake in pancreatic carcinoma and pancreatitis in order to determine if 111In-exendin can be used to discriminate between both diseases * Identification of the cells responsible for uptake of 111In-exendin in the duodenum and pylorus	—

Measure

Time frame

* Validation of the 111In-exendin distribution and accumulation in the pancreas * Determination of the uptake ratio of 111In-exendin between the endocrine and exocrine pancreas by quantitative analysis autoradiography * Determination of the radioactivity concentration in the pancreas by quantitative analysis of SPECT images to validate of in vivo measurement of the pancreatic 111In-exendin uptake * Validation of the correlation between BCM and 111In-exendin uptake (determined ex vivo and in vivo) * Determination of the beta cell function of the patients by oral glucose tolerance testing and arginine stimulation testing to evaluate the relationship between BCM and beta cell function * Determination of 111In-exendin uptake in pancreatic carcinoma and pancreatitis in order to determine if 111In-exendin can be used to discriminate between both diseases * Identification of the cells responsible for uptake of 111In-exendin in the duodenum and pylorus

—

Countries

Netherlands

Outcome results